Report
Rafael Bonardell
EUR 100.00 For Business Accounts Only

BAYER: RDOS. 3T’24 (ANÁLISIS BANCO SABADELL)

Rdos. 3T'24 vs 3T'23:
Ventas: 9.968 M euros (-3,6% vs -1,7% BS(e) y -2,2% consenso);
EBITDA: 1.251 M euros (-25,8% vs -18,0% BS(e) y -22,1% consenso).
Rdos. 9meses'24 vs 9meses'23:
Ventas: 34.877 M euros (-2,5% vs -2,0% BS(e) y -2,1% consenso);
EBITDA: 7.774 M euros (-10,5% vs -9,0% BS(e) y -9,8% consenso).
Underlying
Bayer AG

Bayer is a life sciences group based in Germany. Co.'s operations are organized along three divisions: Pharmaceuticals (engaged in prescription pharmaceuticals for cardiology and women's healthcare); Consumer Health (engaged in non-prescription products in dermatology, dietary supplement, analgesic, gastrointestinal, allergy, cold and flu, foot care, sun protection and cardiovascular risk prevention categories); and CropScience (engaged in the development of seeds and plant traits; crop protection; and for gardens, the green industry and non-agricultural pest control). Co. also maintains an Animal Health business unit engaged in the development of products for farm and companion animals.

Provider
Sabadell
Sabadell

Analysts
Rafael Bonardell

Other Reports on these Companies
Other Reports from Sabadell

ResearchPool Subscriptions

Get the most out of your insights

Get in touch